Apekshya Panda
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Apekshya Panda has a total of 55 co-authors. Here are the top co-authors by number of shared publications:
- Adam S. Fisch
Massachusetts General Hospital 1 Department of Pathology Boston, Massachusetts
57 shared publications - Benjamin J. Gigliotti
Division of Endocrinology, Diabetes, and Metabolism, University of Rochester Medical Center Rochester, New York
57 shared publications - Bryn Reimer
University of Massachusetts Amherst
57 shared publications - Clary B. Clish
Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, USA
57 shared publications - Dora Dias-Santagata
Departments of Pathology Massachusetts General Hospital and Harvard Medical School Boston Massachusetts USA
57 shared publications - Gilbert H. Daniels
Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts
57 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S3 from TBK1 Targeting Is Identified as a Therapeutic Strategy to Enhance CAR T-Cell Efficacy Using Patient-Derived Organotypic Tumor Spheroids
PDOTS patient data (accompanying Fig. 3)
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from TBK1 Targeting Is Identified as a Therapeutic Strategy to Enhance CAR T-Cell Efficacy Using Patient-Derived Organotypic Tumor Spheroids
PDOTS patient data (accompanying Fig. 3)
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from TBK1 Targeting Is Identified as a Therapeutic Strategy to Enhance CAR T-Cell Efficacy Using Patient-Derived Organotypic Tumor Spheroids
Supplemental Figure S4 | Supporting data for ex vivo profiling of PD-1 blockade and TBK1 inhibition in combination with B7-H3.CAR-T cells using PDOTS.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from TBK1 Targeting Is Identified as a Therapeutic Strategy to Enhance CAR T-Cell Efficacy Using Patient-Derived Organotypic Tumor Spheroids
Supplemental Figure S4 | Supporting data for ex vivo profiling of PD-1 blockade and TBK1 inhibition in combination with B7-H3.CAR-T cells using PDOTS.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from TBK1 Targeting Is Identified as a Therapeutic Strategy to Enhance CAR T-Cell Efficacy Using Patient-Derived Organotypic Tumor Spheroids
Supplemental Figure S5 | Supporting data that targeting TBK1 prevents CAR-T cell dysfunction.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from TBK1 Targeting Is Identified as a Therapeutic Strategy to Enhance CAR T-Cell Efficacy Using Patient-Derived Organotypic Tumor Spheroids
Supplemental Figure S5 | Supporting data that targeting TBK1 prevents CAR-T cell dysfunction.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S6 from TBK1 Targeting Is Identified as a Therapeutic Strategy to Enhance CAR T-Cell Efficacy Using Patient-Derived Organotypic Tumor Spheroids
Supplemental Figure S6 | Supporting data that targeting TBK1 prevents CAR-T cell dysfunction.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from TBK1 Targeting Is Identified as a Therapeutic Strategy to Enhance CAR T-Cell Efficacy Using Patient-Derived Organotypic Tumor Spheroids
Supplemental Figure S6 | Supporting data that targeting TBK1 prevents CAR-T cell dysfunction.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S10 from TBK1 Targeting Is Identified as a Therapeutic Strategy to Enhance CAR T-Cell Efficacy Using Patient-Derived Organotypic Tumor Spheroids
Supplemental Figure S10 | Supporting data for single cell RNA sequencing of native tumor-infiltrating lymphocytes following CAR-T challenge in 3D co-cultures with PDOTS.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S10 from TBK1 Targeting Is Identified as a Therapeutic Strategy to Enhance CAR T-Cell Efficacy Using Patient-Derived Organotypic Tumor Spheroids
Supplemental Figure S10 | Supporting data for single cell RNA sequencing of native tumor-infiltrating lymphocytes following CAR-T challenge in 3D co-cultures with PDOTS.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S2 from TBK1 Targeting Is Identified as a Therapeutic Strategy to Enhance CAR T-Cell Efficacy Using Patient-Derived Organotypic Tumor Spheroids
PDOTS patient data (accompanying Fig. 2)
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from TBK1 Targeting Is Identified as a Therapeutic Strategy to Enhance CAR T-Cell Efficacy Using Patient-Derived Organotypic Tumor Spheroids
PDOTS patient data (accompanying Fig. 2)
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from TBK1 Targeting Is Identified as a Therapeutic Strategy to Enhance CAR T-Cell Efficacy Using Patient-Derived Organotypic Tumor Spheroids
Supplemental Figure S3 | Supporting data for ex vivo profiling of B7-H3.CAR-T cells using PDOTS.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from TBK1 Targeting Is Identified as a Therapeutic Strategy to Enhance CAR T-Cell Efficacy Using Patient-Derived Organotypic Tumor Spheroids
Supplemental Figure S3 | Supporting data for ex vivo profiling of B7-H3.CAR-T cells using PDOTS.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S1 from TBK1 Targeting Is Identified as a Therapeutic Strategy to Enhance CAR T-Cell Efficacy Using Patient-Derived Organotypic Tumor Spheroids
PDOTS patient data (accompanying Fig. 1)
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from TBK1 Targeting Is Identified as a Therapeutic Strategy to Enhance CAR T-Cell Efficacy Using Patient-Derived Organotypic Tumor Spheroids
PDOTS patient data (accompanying Fig. 1)
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S11 from TBK1 Targeting Is Identified as a Therapeutic Strategy to Enhance CAR T-Cell Efficacy Using Patient-Derived Organotypic Tumor Spheroids
Supplemental Figure S11 | Supporting data that targeting TBK1 sensitizes cancer cells to CAR-T cell-derived TNFα/IFNγ.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S11 from TBK1 Targeting Is Identified as a Therapeutic Strategy to Enhance CAR T-Cell Efficacy Using Patient-Derived Organotypic Tumor Spheroids
Supplemental Figure S11 | Supporting data that targeting TBK1 sensitizes cancer cells to CAR-T cell-derived TNFα/IFNγ.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S9 from TBK1 Targeting Is Identified as a Therapeutic Strategy to Enhance CAR T-Cell Efficacy Using Patient-Derived Organotypic Tumor Spheroids
Supplemental Figure S9 | Supporting data for single cell RNA sequencing of CAR-T in 3D co-cultures with PDOTS.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S9 from TBK1 Targeting Is Identified as a Therapeutic Strategy to Enhance CAR T-Cell Efficacy Using Patient-Derived Organotypic Tumor Spheroids
Supplemental Figure S9 | Supporting data for single cell RNA sequencing of CAR-T in 3D co-cultures with PDOTS.